ArticleFrontiers in oncology2026
Minimum ADC outperforms PSA and PSA density for predicting ISUP grade group in prostate cancer: a retrospective study of 192 patients undergoing radical prostatectomy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Apparent diffusion coefficient (ADC) derived from diffusion-weighted imaging (DWI) has been proposed as a quantitative biomarker of prostate cancer aggressiveness, and an inverse relationship between ADC and Gleason score has been reported across numerous single-marker studies and meta-analyses. However, most prior work has compared ADC with serum PSA alone, without accounting for PSA density (PSAD) or potential confounders such as age and prostate volume, and without formally testing - using multivariable regression and receiver operating characteristic (ROC) analysis - whether ADC provides incremental diagnostic value beyond PSA-based parameters. Whether the ADC-grade relationship persists after such adjustment, and whether combining ADC with PSA and PSAD meaningfully improves discrimination, remains inconsistently characterized. Objective: To evaluate whether minimum apparent diffusion coefficient (ADC) values are associated with pathological International Society of Urological Pathology (ISUP) Grade Group, and to compare the diagnostic performance of ADC with that of serum PSA and PSA density (PSAD), in patients with histologically confirmed prostate cancer undergoing radical prostatectomy. Methods: A retrospective study of 192 patients undergoing multiparametric MRI (mpMRI), biopsy, and radical prostatectomy was performed. Minimum ADC values were correlated with the final pathological ISUP Grade Group, serum PSA, PSA density, age, and prostate volume. Results: Minimum ADC showed a significant inverse correlation with ISUP Grade Group (Spearman's ρ = -0.355; 95% CI, -0.473 to -0.218; p < 0.001), whereas neither PSA (ρ = 0.012; p = 0.864) nor PSAD (ρ = 0.040; p = 0.578) showed a significant monotonic relationship. On multivariable ordinal logistic regression, minimum ADC remained independently associated with higher ISUP Grade Group after adjustment for age, PSA or PSAD, and prostate volume (OR = 0.995 per 1 × 10 Conclusion: In this radical prostatectomy cohort, minimum ADC was inversely and independently associated with pathological ISUP Grade Group, whereas serum PSA and PSAD were not. ADC substantially outperformed PSA-based markers for discriminating low- from higher-grade disease, although combining ADC with PSA-based parameters provided no significant incremental benefit. These findings support ADC as a promising quantitative imaging biomarker of tumor grade; however, given the retrospective, single-center, surgically selected design and the small number of ISUP Grade Group 1 cases, prospective multicenter validation is required before ADC-based thresholds can be recommended for active surveillance or biopsy decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.